Aeglea Bio Stock Gains On Additional Pegzilarginase Data For Rare Metabolic Disease

Aeglea BioTherapeutics Inc AGLE shared additional data from the PEACE Phase 3 study evaluating Pegzilarginase in Arginase 1 Deficiency.
Arginase-1 deficiency is a rare inherited disorder characterized by a complete or partial lack of the enzyme arginase in the liver and red blood cells. Arginase plays a role in the breakdown and removal of nitrogen from the body, a process known as the urea cycle.
The data were shared at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting.
In an analysis of individual patients, eleven patients (65%) treated with pegzilarginase reached or exceeded prespecified response criteria for at least one mobility assessment compared to four patients (44%) receiving a placebo.
Related: Why Did Aeglea BioTherapeutics Shares Nosedived To 52-Week Low On Monday Premarket?
Eight patients (47%) met or exceeded prespecified clinical response criteria for at least two of the mobility outcomes compared to no patients receiving a placebo.
Six patients meeting or exceeding the clinical response threshold for at least two mobility outcomes showed no worsening on any other mobility endpoint.
In a post hoc analysis correcting for a missed assessment that was improperly scored as 0 rather than "not assessed," the least-squares mean GMFM-D score of pegzilarginase treated patients improved from baseline by 2.25 units to placebo (p=0.0896).
Aeglea submitted an FDA marketing application for pegzilarginase in Arginase 1 Deficiency, and requested for Priority Review.
European marketing application on track for submission this year.
Price Action: AGLE shares are up 27.6% at $3.10 during the premarket session on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs

Aeglea Bio Stock Gains On Additional Pegzilarginase Data For Rare Metabolic Disease

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga